Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Samsung Electronics Shares Jump on HBM4 Mass Production Report 
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
CINCINNATI, OH, March 05, 2018 --
Callitas Health Inc. (CSE: LILY, OTCBB: MPHMF, FWB: T3F2), (the “Company” or “Callitas”) a clinical-stage company developing innovative technologies for weight management and female health and wellness, announced today a new partnership with NFI Consumer Healthcare’s e.p.t®, the Over-The-Counter ("OTC") pregnancy test kit brand.
“ToConceive, our clinically proven fertility lubricant, is a perfect cobranding fit with e.p.t. pregnancy test kits, a category leader in the women’s OTC health market,” stated Callitas CEO James Thompson. “e.p.t.’s brand recognition in the space will help our Company build awareness for the fantastic impact ToConceive can have on couples trying to get pregnant.”
The partnership between NFI and Callitas will include promotional opportunities on shelf, product samples and new product inclusion at major food, drug and mass retailers throughout the United States.
“After purchasing EPT in 2017, our group began working on potential line extensions for the brand that would emerge it from only being a pregnancy test brand to becoming part of the complete family planning process,” said Benjamin Blessing, EVP of Sales and Marketing for NFI Consumer Products.
“Developing a packaging concept that included the ToConceive product just made sense to us,” Blessing said. “This is a brand completely devoted to helping women fulfill their desire to become pregnant. We are pleased to have a product that may facilitate a long-anticipated and life changing pregnancy.”
About Callitas Health
Formed in early 2015, Callitas Health Inc. is a clinical-stage company developing innovative technologies for obesity, weight management and female health & wellness. In addition to its recent acquisitions of C-103, a reformulation of Orlistat, Extrinsa and assets from 40J’s LLC, the Company successfully launched ToConceive in North America as a clinically proven option for couples struggling with the inability to conceive. www.toconceive.com.
Callitas Health Inc. trades on the Canadian Securities Exchange (CSE) under the ticker symbol “LILY” as well as on the OTCQB as “MPHMF” and FWB (Frankfurt Stock Exchange) as “T3F2.”
For more information contact: James Thompson, CEO, or Callitas Investor Relations Phone: +1 (859) 868-3131 www.callitas.com
